

# Restoring Lives



## Integra at a Glance

Today, the Company has more than \$1.5 billion in global revenue, with market-leading brands sold in 130 countries. Integra manufactures and sells medical technologies and products in two reportable business segments: Codman Specialty Surgical, also known as CSS, and Tissue Technologies.

We have an advanced position in the medical device industry as a result of:

- Achieving no. 1 or 2 position in attractive markets
- Depth and breadth of portfolio and technologies
- Tenured, trusted salesforce and channels
- Global footprint for technology access and commercialization
- Strong balance sheet and financial discipline
- Systematic M&A aimed at accretive growth segments

1989

Founded

3,946

Colleagues

~90%

Recurring/  
Consumables


### REVENUE FY2023

\$1.54B

### BY PRODUCT CATEGORY

69%

Codman  
Specialty  
Surgical




31%

Tissue  
Technologies

### BY GEOGRAPHY

71%

U.S.



29%

International

14

Manufacturing Sites

3

Primary Global  
Third-Party Logistics  
Distribution Centers

130

Countries Served

220+

Distributor Partners

# Our Business Segments

## Codman Specialty Surgical

Codman Specialty Surgical consists of market-leading technologies and instrumentation for a wide range of specialties, such as neurosurgery, neurocritical care, otolaryngology and otorhinolaryngology. Integra is the world leader in neurosurgery med tech, and our global scale allows us to offer solutions across multiple disease states like brain lesion surgery, including minimally invasive techniques; traumatic brain injury care and neuromonitoring; and hydrocephalus care. We are also one of the top three providers of instruments used in precision, specialty and general surgical, and now also ENT procedures from recently acquired Acclarent, Inc.





## Tissue Technologies

The Tissue Technologies segment focuses on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. This segment of our business represents the broadest set of regenerative technology platforms in the industry, ranging from highly engineered collagen technologies to bovine dermis, porcine and amniotic tissue, and bioabsorbable matrix.



### REVENUE FY2023

\$1.0B



### LEADING BRANDS

MAYFIELD  
CUSA®  
Certas® Plus  
Bactiseal®  
ICP Express®

ISOCOOL®  
Integra® DUO  
TruDi®  
AERA®



New Product Innovation

**\$18.9M**      **+62%**

Revenue      Increase from 2022

### REVENUE FY2023

\$0.5B



### LEADING BRANDS

Integra® Dermal Matrices  
Gentrix®  
DuraSorb®  
PriMatrix®

MicroMatrix®  
SurgiMend®  
MediHoney®

New Product Innovation

**\$2.1M**      **+175%**

Revenue      Increase from 2022

# Integrated Growth Strategy

In 2023, Integra maintained its focus on the five pillars of our integrated growth strategy established in 2022. These pillars are comprised of three growth drivers—levers that directly impact the Company’s growth ambitions—and two enablers that make integrated growth possible. This approach continues to enable us to strengthen operational capacity and efficiency and accelerate innovation and growth, and in 2023 led to key accomplishments in each of the pillars.

## DRIVING AN INTEGRATED GROWTH STRATEGY

Strengthening Operational Capability and Efficiency, Accelerating Innovation and Growth

### GROWTH DRIVERS

Innovate  
for Outcomes



Grow  
International



Broaden Impact  
on Care Pathways



### ENABLERS

Drive Operations and  
Customer Excellence



Cultivate a  
High-Performance Culture



## 2023 ACCOMPLISHMENTS

- Relaunched CereLink® in international markets; submitted 510(k) for CereLink in the U.S.
- Submitted clinical PMA amendment for SurgiMend
- Completed enrollment in DuraSorb® PMA trial
- Obtained 510(k) for next generation Aurora® Surgiscope
- Opened regenerative technology innovation and learning center in Plainsboro, New Jersey

- High single-digit growth in international markets
- Double-digit growth in China
- International portfolio expansion of DuraGen®, CUSA and 100+ product registrations
- Realignment of international organization, building local commercial capabilities
- Buildout of In-China-for-China (ICFC) manufacturing capability

- Signed definitive agreement to acquire the Acclarent® ENT business
- Successful commercial and clinical integration of SIA acquisition
- Double-digit growth in UBM platform
- Finalized market research and design for digital innovation pilots


- Expanded Le Locle, Switzerland site, enabling launch of differentiated NPIs
- Established ICFC manufacturing capacity, ready for 2024 validation
- Strengthened plant management and quality leadership
- Invested in manufacturing capacity and resilience
- Enhanced procurement category management
- Deepened plant level KPI measurement

- Awarded Great Place to Work in China
- Formed UNIDOS employee resource group
- Further strengthened executive leadership team with key hires and capabilities



# 2023 Highlights

## Environmental



**Improved GHG emission data collection** through process improvement, which allowed us to calculate our emissions with fuel and electricity usage compared to spend data in 2021

**Conducted energy reduction assessments** to identify opportunities that can be applied to worldwide operations

**~32,000**

Devices were Maintained through our Service and Repair Facilities

## Social

**7M+**

Patients Touched

**\$4.63M**

In Products Donated

**\$417K+**

In Grant Donations by the Integra Foundation to **67 nonprofits**

**82%**


Participation Rate in Colleague Engagement Surveys

**~1 in 5**

Colleagues are Members of an ERG

**~125**

Events Held by Our **7 ERGs**



## Governance

**100%**

Of Employees Completed Code of Conduct and Anti-Bribery and -Corruption Training

**100%**


Of New Hires Completed Unconscious Bias Training

**33%**

Of Our Board Members are Women

**22%**

Of Our Board Members are from Ethnically Diverse Backgrounds



Opened a **new research and development facility** dedicated to pioneering new advances in treatment pathways



**INTEGRA LIFESCIENCES**

1100 Campus Road, Princeton, New Jersey 08540

[WWW.INTEGRALIFE.COM/ESG-REPORT](http://WWW.INTEGRALIFE.COM/ESG-REPORT)

